Ozone therapy continues to draw growing peer-reviewed research interest as a complementary tool in integrative medicine. Here’s a roundup of recent notable developments spanning a new wearable delivery device, stroke recovery data, and cancer-support applications.

Table of Contents

• A Wearable Approach to Drug-Resistant Wounds
• Stroke Recovery Data
• Ozone as Complementary Cancer Support
• Faster Healing for Chronic Facial Wounds
• Why This Matters
• Conclusion

A Wearable Approach to Drug-Resistant Wounds

Researchers published a study in Advanced Therapeutics describing a smart wearable ozone therapy system designed to treat multidrug-resistant (MDR) bacterial wound infections. Chronic non-healing wounds affect an estimated 10.5 million people in the US and cost Medicare between $28.1 and $96.8 billion annually, with drug-resistant infections a growing complication as antibiotic resistance rises. The device combines ozone’s antimicrobial action with bio-stimulatory healing effects in a single wearable format, an approach the researchers say outperforms conventional single-mechanism treatments like silver dressings or standalone phototherapy in early testing.

Stroke Recovery Data

A 2025 clinical trial published in Frontiers in Medicine compared ozone therapy against traditional antioxidant drugs in patients recovering from acute ischemic stroke, finding that ozone outperformed the comparator on both neurological recovery measures and safety profile. The proposed mechanism centers on ozone’s activation of HIF-1α (hypoxia-inducible factor 1-alpha), which improves oxygen delivery to tissue affected by reduced blood flow — the same pathway researchers point to in ozone’s effects on other vascular and circulatory conditions, including peripheral artery disease and diabetic foot ulcers.

Ozone as Complementary Cancer Support

A 2025 scoping review evaluated medical ozone as a complementary approach for managing cancer-related pain, fatigue, anxiety, and depression, concluding it shows promise with a favorable safety profile when used alongside standard oncology care. This adds to a body of smaller clinical studies from Spanish research groups examining ozone for cancer-treatment-related pelvic pain and chemotherapy-induced peripheral neuropathy, an area that continues to see active clinical trial enrollment.

Faster Healing for Chronic Facial Wounds

A single-arm clinical study published in the Journal of Maxillofacial and Oral Surgery evaluated topical ozone therapy in 11 patients with chronic facial wounds. Pain scores dropped sharply, from a mean of 7.09 on day one to 2.81 by day three, with no reported pain by day seven. Wound size decreased correspondingly, from 14.3 cm² on day one to 0.68 cm² by day seven — a small study, but a striking healing trajectory that supports larger controlled trials.

Why This Matters

Taken together, these studies reflect a field maturing beyond anecdotal use toward device innovation and rigorous outcome measurement. Evidence quality remains moderate by conventional standards — several of the strongest findings still come from small or single-arm studies — but the mechanistic consistency across wound healing, vascular conditions, and inflammatory pain points to biologically plausible pathways (HIF-1α activation, antimicrobial action, immune modulation) that researchers are now testing more rigorously. For integrative and regenerative practices, this is a field worth watching for practice-relevant protocol updates as larger randomized trials mature.

Conclusion

Ozone therapy research is expanding from established uses in pain and wound care into higher-stakes areas like stroke recovery and oncology support. Larger randomized controlled trials will be the next test of whether these early signals hold up at scale.

Sources

• Advanced Therapeutics (Wiley), “Smart Wearable Ozone Therapy System for Managing Multidrug-Resistant Wound Infections” — Read here
• Journal of Maxillofacial and Oral Surgery (Springer Nature), “Role of Topical Ozone Therapy in the Management of Chronic Facial Wounds: A Single-Arm Clinical Study” — Read here
• TopDoctor Magazine, “Ozone Therapy: The Complete Science-Backed Guide (2026)” — Read here

The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee meets July 29 to review Capricor Therapeutics’ deramiocel, an investigational allogeneic cell therapy for Duchenne muscular dystrophy. The meeting comes ahead of an August 22 target decision date and follows a prior rejection of the company’s first application.

Table of Contents

• What’s Happening
• How Deramiocel Works
• What the Data Show
• Why This Matters
• Conclusion

What’s Happening

On July 29, 2026, the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee will convene to review Capricor Therapeutics’ Biologics License Application for deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD). The Federal Register notice confirming the meeting’s final details was amended on July 24, 2026, and the session will be livestreamed for public viewing.

This is Capricor’s second attempt at approval. The FDA rejected the company’s original application, based primarily on Phase 2 data, with a complete response letter citing substantial-evidence and manufacturing (CMC) deficiencies. The agency has since rescinded that letter and is now reviewing a resubmitted application built on additional Phase 3 data, with a PDUFA target action date of August 22, 2026.

How Deramiocel Works

Deramiocel (also known as CAP-1002) is an allogeneic, off-the-shelf cell therapy made from human cardiosphere-derived cells. Administered by infusion, it’s designed to reduce inflammation and support tissue repair in both skeletal and cardiac muscle — the two systems progressively damaged by DMD. If approved, it would be the first therapy to address both the skeletal and cardiac manifestations of the disease in a single product, a distinction that matters given that cardiomyopathy is a leading cause of death in DMD patients.

Deramiocel holds Orphan Drug designation in both the US and EU, Regenerative Medicine Advanced Therapy (RMAT) and Rare Pediatric Disease designations in the US, and Advanced Therapy Medicinal Product (ATMP) status in the EU — the last of which may qualify Capricor for a Priority Review Voucher if approved.

What the Data Show

The resubmitted BLA is supported by the Phase 2 HOPE-2 trial and its long-term HOPE-2-OLE extension, along with topline results from the Phase 3 HOPE-3 trial. HOPE-2 showed a 36.2% benefit on a mid-level elbow measure of upper limb function (PUL) versus placebo at 12 months, along with reduced cardiac injury markers (CK-MB and total CK), suggesting less myocardial damage.

HOPE-3 met its primary endpoint, showing a 54% slowing of disease progression on the PUL v2.0 scale, and its key cardiac endpoint showed a 91% slowing in the decline of left ventricular ejection fraction (LVEF) by central cardiac MRI — a marker of heart muscle function. The trial also met additional controlled secondary endpoints.

Why This Matters

For the regenerative and integrative medicine community, this advisory committee meeting is a bellwether moment for cell therapy in a devastating pediatric disease with no treatment that addresses both its muscular and cardiac components. An advisory committee’s recommendation isn’t binding, but it heavily influences the FDA’s final decision and signals how regulators are weighing benefit-risk tradeoffs for allogeneic cell products more broadly. A second look at a previously rejected application, now backed by Phase 3 data, also illustrates how sponsors are increasingly able to iterate through FDA’s regenerative medicine pathways rather than face a single make-or-break review.

Conclusion

The July 29 advisory committee meeting is a critical checkpoint on deramiocel’s path to potential approval by August 22. A positive recommendation would move a first-in-class dual-benefit cell therapy closer to patients; a negative one would raise fresh questions about the regulatory bar for allogeneic cell products in rare pediatric disease.

Sources

• NeurologyLive, “FDA Advisory Committee Schedules Meeting to Review Deramiocel’s BLA in Duchenne Muscular Dystrophy” — Read here
• GlobeNewswire / Capricor Therapeutics, “Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy” — Read here
• Federal Register, “Cellular, Tissue, and Gene Therapies Advisory Committee; Amendment of Notice” — Read here

The FDA has approved Tregzi, a precision-engineered cell therapy from Orca Bio, as the first regulatory T-cell (Treg) based treatment for adults undergoing allogeneic stem cell transplants for blood cancers. Trial data showed it more than doubled one-year survival free of chronic graft-versus-host disease compared with standard transplants.

Table of Contents

• What Happened
• How Tregzi Works
• What the Data Show
• Why This Matters
• Conclusion

What Happened

On June 30, 2026, the FDA approved Tregzi (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq), developed by Orca Bio and previously known as Orca-T. It is indicated for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (GVHD)-free survival in adults with hematologic malignancies. The approval makes Tregzi the first FDA-cleared therapy built on highly purified regulatory T cells, and only the second cell therapy ever approved specifically in the GVHD setting, following Mesoblast’s Ryoncil.

Tregzi received Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations ahead of filing, along with Priority Review. The FDA’s target action date was extended from April to July 2026 after the agency requested additional manufacturing information.

How Tregzi Works

Tregzi reformulates a standard allogeneic stem cell transplant rather than replacing it outright. Instead of infusing an unmodified mix of stem and immune cells from a matched donor, it separates the donor material into components: hematopoietic stem and progenitor cells to rebuild the patient’s blood and immune system, highly purified regulatory T cells to suppress the immune attack that causes GVHD, and a follow-up dose of conventional T cells to help clear residual cancer cells. The goal is to preserve the beneficial graft-versus-leukemia effect of a transplant while reducing the collateral immune damage that has long made GVHD one of the field’s most difficult trade-offs.

What the Data Show

Approval was based on the Phase 3 PRECISION-T trial, a randomized, open-label study of 187 adults with blood cancers, including acute leukemia and myelodysplastic syndrome, across 19 transplant centers. Patients received either Tregzi with single-agent tacrolimus, or a standard transplant with a combination of tacrolimus and methotrexate.

At one year, 78.0% of Tregzi recipients achieved chronic GVHD-free survival, compared with 38.4% in the standard transplant group. After accounting for death as a competing risk, serious chronic GVHD developed in 12.6% of Tregzi patients versus 44.0% of controls. Safety data also favored Tregzi: Grade 3 or 4 acute GVHD at day 180 occurred in 6% of Tregzi recipients versus 10% with standard transplant, alongside fewer serious infections.

Why This Matters<